After a horrid six to eight weeks in the biotech sector, shares are starting recently to reboundThe debacle in biotech that occurred from March on was one of the most violent sector rotations the market has seen in quite some timeHuge biotechs like Celgene (CELG) and Gilead Sciences (GILD) lost 15% to 25% of their value from peak to through over t...
Read the full story and get access to the Real Money Pro trading floor.
There's no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.